Moreover, pre-existing immunity (high expression of CD274, T cell effector signature and intratumoral CD8+ T cell density), high expression of Treg, MDSC and VEGFR2 in tumor tissue could also be potential candidate biomarkers for prediction of response and resistance to ICI and anti-angiogenic combination therapy (274). This evidence concerns the gene CD8A and neoplasm.